Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EJErin Jou

Discussion

Loading...

Member takes

Overview

Analysis reveals TP53-mutated AML shows similar outcomes with hypomethylating agents and venetoclax, suggesting treatment implications.

Key Points

  • Overall survival was similar for TP53-mutated AML patients receiving hypomethylating agent and venetoclax therapy.
  • Survival outcomes were assessed using log-rank testing among 957 AML cases, highlighting the significance of allelic status.
  • Induction therapy included a combination of hypomethylating agents and venetoclax for a substantial proportion of patients.
  • Significantly improved survival was observed in single-hit patients receiving intensive chemotherapy compared to double-hit cases.

Cite This Study

Erin Jou (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3dchttps://doi.org/10.1182/blood-2025-1705
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights2025
  2. 2Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy2025
  3. 3Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  4. 4Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.2025
  5. 5Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations